Irsogladine
Names | |
---|---|
Preferred IUPAC name 6-(2,5-Dichlorophenyl)1,3,5-triazine-2,4-diamine | |
Other names DCPDAT | |
Identifiers | |
CAS Number |
|
ChemSpider |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Properties | |
Chemical formula | C9H7Cl2N5 |
Molar mass | 256.09 g·mol−1 |
Pharmacology | |
A02BX16 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references |
Chemical compound
Irsogladine is a phosphodiesterase inhibitor.[1]
References
- ^ Satoh, H; Amagase, K; Takeuchi, K (2013). "Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats". The Journal of Pharmacology and Experimental Therapeutics. 348 (2): 227–35. doi:10.1124/jpet.113.208991. PMID 24254524. S2CID 23740642.
- v
- t
- e
Drugs for peptic ulcer and GERD/GORD (A02B)
- Cimetidine
- Famotidine
- Lafutidine
- Lavoltidine (loxtidine)
- Nizatidine
- Ranitidine#‡
- Roxatidine
analogues ("-prost-")
("-prazole")
acid blockers ("-prazan")
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
- See also: Helicobacter pylori eradication protocols
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This article about an organic compound is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e